UK markets close in 17 minutes

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
10.88+0.22 (+2.04%)
As of 11:12AM EDT. Market open.

Aerie Pharmaceuticals, Inc.

4301 Emperor Boulevard
Suite 400
Durham, NC 27703
United States
919 237 5300
https://www.aeriepharma.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees376

Key executives

NameTitlePayExercisedYear born
Mr. Raj KannanCEO, Principal Financial Officer & Director753.49kN/A1964
Dr. Casey C. Kopczynski Ph.D.Co-Founder, Chief Innovation Officer & Head of Research and External Innovation685.06k983.39k1961
Mr. John W. LaRocca Esq.Gen. Counsel & Sec.676.62kN/A1965
Mr. Peter F. LangChief Financial OfficerN/AN/A1972
Dr. Michelle Senchyna Ph.D.Head of Clinical Devel. & OperationsN/AN/AN/A
Mr. Jeffrey M. Calabrese CPAVP of Fin. & Principal Accounting OfficerN/AN/A1967
Ms. Carolyn McAuliffeSr. Director of CommunicationsN/AN/AN/A
Ms. Wanda FranciesHead of HRN/AN/AN/A
Mr. Marvin J. GarrettHead of Regulatory Affairs & Quality AssuranceN/AN/A1951
Mr. Craig R. SkenesHead of Bus. Devel.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Corporate governance

Aerie Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 July 2022 is 6. The pillar scores are Audit: 3; Board: 5; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.